To the Editor We read with interest the report on the long-term recurrence and survival outcomes after treatment with delayed second-procedure targeted intraoperative radiotherapy (IORT) vs whole-breast radiotherapy by Vaidya et al.1 Since the publication of 5-year outcomes from the TARGIT-A trial,2 the oncology community has awaited long-term outcomes from the study to evaluate the utility of IORT for early breast cancer. The recent publication of the delayed-treatment cohort of patients from the TARGIT-A trial has now provided additional information. The study found that 5-year local recurrence rates were 3.96% with delayed second-procedure IORT compared with 1.05% with whole-breast irradiation (WBI), which was not noninferior. No difference in mastectomy-free survival, distant disease-free survival, or overall survival was noted.1
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Shah C, Wazer D, Vicini F. Targeted Intraoperative Radiotherapy for Early Breast Cancer. JAMA Oncol. 2020;6(10):1635–1636. doi:10.1001/jamaoncol.2020.2713
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: